Chiasma, Inc. (CHMA) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Chiasma, Inc. (CHMA) trades at $3.76 with AI Score 56/100 (Grade B). Chiasma, Inc. is a clinical late-stage biopharmaceutical company focused on developing oral medications for rare chronic diseases. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 10, 2026Analyst Coverage for CHMA: CHMA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CHMA against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
CHMA: the 3 scored disciplines are evenly split. Dominant signal: Seth Klarman bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Chiasma, Inc. (CHMA) Healthcare & Pipeline Overview
Chiasma, Inc. leverages its proprietary transient permeability enhancer technology to develop oral therapies for rare diseases, positioning itself as a leader in innovative treatments for chronic conditions like acromegaly.
What Is the Investment Thesis for CHMA?
Chiasma, Inc. presents a compelling investment thesis driven by its innovative oral drug delivery system and the significant market potential for its lead product, MYCAPSSA. The global acromegaly treatment market is expected to grow substantially, with estimates suggesting a CAGR of 5-7% through 2030, driven by increasing diagnoses and advancements in treatment options. As MYCAPSSA progresses through its Phase III trials, successful outcomes could lead to FDA approval, significantly enhancing revenue potential. Additionally, the company’s high gross margin of 94.5% indicates strong profitability potential upon commercialization. However, investors should remain cautious of the risks associated with regulatory approvals and market competition, which could impact timelines and market entry.
Based on FMP financials and quantitative analysis
CHMA Key Highlights
Gross margin of 94.5% indicates strong potential for profitability upon product launch.
- Currently in Phase III clinical trials for MYCAPSSA, targeting a significant unmet need in acromegaly treatment.
- Founded in 2001, Chiasma has over two decades of experience in the biopharmaceutical sector.
- Employee base of 84 reflects a focused team dedicated to advancing innovative therapies.
- No dividend yield indicates a reinvestment strategy focused on growth and product development.
Who Are CHMA's Competitors?
CHMA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| HUM Humana Inc. | $381.21 | +0.84% | $45.8B | 50 |
| SNY Sanofi | $45.44 | -0.85% | $109B | 58 |
| NVS Novartis AG | $160.31 | +3.73% | $305B | 57 |
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ALNY Alnylam Pharmaceuticals, Inc. | $242.61 | +6.12% | $32.5B | 92 |
| RPRX Royalty Pharma plc | $60.58 | -1.86% | $26.9B | 75 |
| INCY Incyte Corporation | $127.80 | -0.53% | $25.9B | 99 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CHMA's Key Strengths?
Innovative oral delivery system enhances patient compliance and convenience.
- High gross margin potential indicates strong profitability upon product launch.
- Focused expertise in rare diseases positions the company favorably in a niche market.
- Strong leadership with a clear vision for product development and commercialization.
What Are CHMA's Weaknesses?
Currently lacks diversified product offerings beyond MYCAPSSA.
- High dependency on the success of a single product in clinical trials.
- Limited financial resources due to negative profit margins.
- Small employee base may restrict operational scalability.
What Could Drive CHMA Stock Higher?
Completion of Phase III clinical trials for MYCAPSSA, expected in Q4 2026.
- Engagement with regulatory agencies for potential FDA approval of MYCAPSSA.
- Expansion of clinical trials to include additional indications for MYCAPSSA.
- Development of partnerships for distribution and marketing of MYCAPSSA.
- Presentation of clinical trial results at major industry conferences in 2026.
What Are the Key Risks for CHMA?
Negative return on equity (-84.2%) — the business is not currently generating profit on shareholder capital.
- Regulatory approval process may introduce delays or rejections.
- Market competition from established therapies could impact MYCAPSSA's market share.
- Dependence on a single product increases vulnerability to market fluctuations.
- Economic factors may affect healthcare spending and patient access to treatments.
What Are the Growth Opportunities for CHMA?
- Growth opportunity 1: The acromegaly treatment market is projected to grow at a CAGR of 5-7%, reaching approximately $2 billion by 2030. Chiasma's MYCAPSSA, as an oral alternative to injectable therapies, is poised to capture significant market share due to its enhanced patient compliance and convenience.
- Growth opportunity 2: Expansion into international markets presents a substantial opportunity for Chiasma. As MYCAPSSA gains regulatory approvals in regions outside the U.S., the company could tap into a global market for acromegaly treatment, potentially increasing revenue streams significantly.
- Growth opportunity 3: The ongoing development of additional formulations using Chiasma's transient permeability enhancer technology could lead to new product offerings. This diversification strategy may allow the company to enter other therapeutic areas, further expanding its market presence.
- Growth opportunity 4: Collaborations with larger pharmaceutical companies for distribution and marketing could enhance Chiasma's reach and accelerate commercialization timelines. Strategic partnerships may provide the necessary resources for scaling operations and expanding market access.
- Growth opportunity 5: Increased awareness and diagnosis of acromegaly and related conditions could drive demand for MYCAPSSA. As healthcare providers become more educated about these rare diseases, the potential patient population for Chiasma's product may expand, leading to higher sales.
What Threats Does CHMA Face?
- Intense competition from established players in the biotechnology sector.
- Regulatory hurdles may delay product approvals and market entry.
- Market acceptance of new therapies can be unpredictable and challenging.
- Economic downturns could impact healthcare spending and patient access to treatments.
What Are CHMA's Competitive Advantages?
- Proprietary transient permeability enhancer technology provides a competitive edge in oral drug delivery.
- Focus on rare diseases limits competition and enhances market positioning.
- Strong gross margin potential allows for reinvestment in R&D and marketing efforts.
- Established clinical trial infrastructure supports efficient product development.
- Commitment to patient adherence and outcomes strengthens brand loyalty and market trust.
What Does CHMA Do?
Founded in 2001 and headquartered in Needham, Massachusetts, Chiasma, Inc. is a clinical late-stage biopharmaceutical company dedicated to transforming the treatment landscape for patients with rare and serious chronic diseases. The company’s innovative approach utilizes a proprietary transient permeability enhancer technology platform, enabling the development of oral medications that improve patient adherence and outcomes. Chiasma's flagship product, MYCAPSSA, is an oral formulation of octreotide, currently undergoing Phase III clinical trials for the treatment of acromegaly, a condition characterized by excessive growth hormone production. This product aims to provide a more convenient alternative to traditional injectable therapies, addressing a significant unmet need in the market. With a workforce of 84 employees, Chiasma is committed to advancing its pipeline and expanding its impact in the biopharmaceutical sector. The company’s focus on rare diseases not only highlights its commitment to improving patient lives but also positions it strategically within a growing market that demands innovative solutions.
What Products and Services Does CHMA Offer?
- Develops oral medications for rare chronic diseases using proprietary technology.
- Focuses on the treatment of acromegaly with its lead product, MYCAPSSA.
- Conducts late-stage clinical trials to validate the efficacy and safety of its products.
- Aims to improve patient adherence to treatment through innovative oral delivery systems.
- Targets global markets for rare disease treatments, enhancing patient access to therapies.
- Engages in research and development to expand its product pipeline and therapeutic offerings.
How Does CHMA Make Money?
- Generates revenue through the development and commercialization of innovative biopharmaceutical products.
- Focuses on the sale of MYCAPSSA, which targets a niche market of acromegaly patients.
- Invests in R&D to create proprietary formulations that can be marketed globally.
- Seeks partnerships and collaborations to enhance distribution and market penetration.
- Utilizes a high-margin product strategy to maximize profitability upon successful product launches.
What Industry Does CHMA Operate In?
The biotechnology industry is experiencing robust growth, driven by advancements in drug development technologies and an increasing focus on personalized medicine. Chiasma, Inc. operates within this dynamic landscape, focusing on oral medication solutions that enhance patient compliance and treatment efficacy. As competition intensifies, companies that can offer differentiated products, like Chiasma’s MYCAPSSA, are well-positioned to capture market share in this lucrative sector.
Who Are CHMA's Key Customers?
- Patients diagnosed with acromegaly seeking effective treatment options.
- Healthcare providers and specialists in endocrinology who prescribe treatments.
- Pharmaceutical distributors and wholesalers that facilitate product availability.
- Insurance companies that reimburse for innovative therapies for rare diseases.
- Global healthcare systems aiming to improve patient outcomes in chronic disease management.
Earnings Track Record
Chiasma, Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 9.1% below estimates on average.
CHMA Valuation & Market Position
Relative to its peer group, CHMA's quantitative score of 56/100 is below the peer average of 71/100.
Key Financial Metrics
Return on equity for Chiasma, Inc. stands at -84.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -42.4%, showing how much profit it generates from its asset base. A current ratio of 9.17 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -38.1%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
Chiasma, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Needham, US. The company is led by CEO Raj Kannan. CHMA has traded publicly since 2015.
CHMA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Innovative oral delivery system enhances patient compliance and convenience.
- High gross margin potential indicates strong profitability upon product launch.
- Focused expertise in rare diseases positions the company favorably in a niche market.
- Strong leadership with a clear vision for product development and commercialization.
Bear Case
- Currently lacks diversified product offerings beyond MYCAPSSA.
- High dependency on the success of a single product in clinical trials.
- Limited financial resources due to negative profit margins.
- Small employee base may restrict operational scalability.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
CHMA Latest News
No recent news available for CHMA.
CHMA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CHMA.
Price Targets
Wall Street price target analysis for CHMA.
CHMA MoonshotScore
What does this score mean?
The MoonshotScore rates CHMA 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Raj Kannan
CEO
Raj Kannan has extensive experience in the biopharmaceutical industry, having held various leadership roles in both large pharmaceutical companies and startups. He holds a degree in pharmacy and an MBA, equipping him with a strong foundation in both science and business. Prior to joining Chiasma, Raj was instrumental in advancing several drug development projects at leading firms, demonstrating his capability in navigating complex regulatory environments.
Track Record: Under Raj Kannan's leadership, Chiasma has successfully advanced MYCAPSSA through critical clinical trial phases, positioning the company for potential market entry. His strategic focus on innovation and patient-centered solutions has been pivotal in shaping the company's vision and operational strategies.
Chiasma, Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for CHMA?
CHMA holds an AI Score of 56/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Chiasma, Inc. is a clinical late-stage biopharmaceutical company focused on developing oral medications for rare chronic diseases. Its lead product, MYCAPSSA, targets acromegaly and is currently …
What does Chiasma, Inc. do?
Chiasma, Inc. is a biopharmaceutical company focused on developing oral medications for rare chronic diseases, primarily targeting acromegaly with its lead product, MYCAPSSA. The company utilizes a proprietary transient permeability enhancer technology platform to create innovative therapies that improve patient adherence and outcomes.
What do analysts say about CHMA stock?
Analysts generally view CHMA stock with cautious optimism, highlighting the potential of MYCAPSSA in the acromegaly market. Key valuation metrics indicate a focus on future revenue growth, especially as the company approaches critical clinical trial milestones and potential FDA approval.
What are the main risks for CHMA?
Chiasma faces several risks, including the regulatory approval process for MYCAPSSA, which could delay market entry or result in rejection. Additionally, competition from established therapies poses a threat to market share, while reliance on a single product increases vulnerability to fluctuations in demand and market conditions.
What are the key factors to evaluate for CHMA?
Chiasma, Inc. (CHMA) holds an AI score of 56/100 (moderate). presents a compelling investment thesis driven by its innovative oral drug delivery system and the significant market potential for its lead product, MYCAPSSA. Not financial advice.
How frequently does CHMA data refresh on this page?
CHMA's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven CHMA's recent stock price performance?
Chiasma, Inc. (CHMA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative oral delivery system enhances patient compliance and convenience. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CHMA overvalued or undervalued right now?
Chiasma, Inc. (CHMA) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research CHMA before investing?
Before investing in Chiasma, Inc. (CHMA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.